What treatment would you recommend for a patient with early-stage TNBC treated per KEYNOTE-522, PD-L1 CPS >10, with metastatic recurrence within 12 months of treatment completion?
Is there a duration of time during which you would not re-challenge with immunotherapy?
Community PollStarted
What treatment would you recommend for a patient with early-stage TNBC treated per KEYNOTE-522, PD-L1 CPS >10, with metastatic recurrence within 12 months of treatment completion?
51 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Duke University
Answered on · Updated on
In the absence of a clinical trial option for this patient with triple-negative breast cancer (TNBC) who had completed the KEYNOTE-522 regimen <12 months ago for non-metastatic TNBC and who now has metastatic TNBC which tested PD-L1 positive (PD-L1 CPS >10), I would offer immunotherapy with pembroli...
Join for free or sign in to see the full answer